IRLAB Therapeutics

IRLAB is a clinical-stage biotech transforming the treatment of Parkinson’s disease.

[IRLAB Therapeutics @IRLABThera]

Look at the full lenght interview with CEO Nicholas Waters on Edison Open House - Global Healthcare 2022.
https://t.co/wgXR4mRO3M

[Edison @Edison_Inv_Res]

Hear first-hand from IRLAB Therapeutics CEO Dr Nicholas Waters and deep dive into how the company is developing novel #drugs to treat #neurodegenerative diseases. 👩‍🔬 $IRLAB #Parkinsons #disease #therapeutics https://t.co/gPj9qYgsTn

[IRLAB Therapeutics @IRLABThera]

IRLAB:s ansökan om IND för mesdopetam godkänd av FDA ​​​​​​​ https://t.co/5URzWd7zRZ

[IRLAB Therapeutics @IRLABThera]

IRLAB's mesdopetam IND accepted by the US FDA https://t.co/5skBEnQMjn

[IRLAB Therapeutics @IRLABThera]

IRLAB's shares are now traded on Nasdaq Stockholm Main Market ​​​​​​​ https://t.co/5cAqgjQG3O

[IRLAB Therapeutics @IRLABThera]

IRLAB:s aktie handlas från idag på Nasdaq Stockholms huvudlista https://t.co/hZMyqX2d94

[IRLAB Therapeutics @IRLABThera]

IRLAB publishes prospectus in connection with its listing on Nasdaq Stockholm Main Market https://t.co/aAIPjNXGVW

[IRLAB Therapeutics @IRLABThera]

IRLAB offentliggör prospekt i samband med notering på Nasdaq Stockholms huvudlista https://t.co/QTgeg2LjKy

[IRLAB Therapeutics @IRLABThera]

IRLAB Therapeutics har godkänts för notering på Nasdaq Stockholms huvudlista https://t.co/cxhxyD8fPC

[IRLAB Therapeutics @IRLABThera]

IRLAB Therapeutics has been approved for listing on Nasdaq Stockholm Main Market https://t.co/3Lgfuwfp0X

[IRLAB Therapeutics @IRLABThera]

IRLAB:s läkemedelskandidat pirepemat presenteras på omslaget av topprankade vetenskapliga tidskriften JPET https://t.co/2wXUdyQXSI

[IRLAB Therapeutics @IRLABThera]

IRLAB’s drug candidate pirepemat featured on cover of top-tier journal JPET ​​​​​​​ https://t.co/l62aE04iiz

[IRLAB Therapeutics @IRLABThera]

IRLAB delårsrapport januari – juni 2020 https://t.co/GMFj1RtNV1

[IRLAB Therapeutics @IRLABThera]

IRLABs IRL752 föreslås få det unika INN-namnet pirepemat av WHO https://t.co/so2aDFpwPn

[IRLAB Therapeutics @IRLABThera]

IRLAB’s IRL752 is proposed pirepemat as a unique INN by WHO ​​​​​​​ https://t.co/Cky2VcLDwb

[IRLAB Therapeutics @IRLABThera]

IRLAB:s kliniska läkemedelskandidat IRL752 publicerad i JPET https://t.co/88Es3ddLij

[IRLAB Therapeutics @IRLABThera]

IRLAB’s clinical drug candidate IRL752 published in JPET ​​​​​​​ https://t.co/L1y8wHG95X

[IRLAB Therapeutics @IRLABThera]

IRLABs mesdopetam presenteras på omslaget av topprankade vetenskapliga tidskriften JPET https://t.co/XOzxhX1pDO

[IRLAB Therapeutics @IRLABThera]

IRLAB’s mesdopetam featured on cover of top-tier publication JPET ​​​​​​​ https://t.co/LqRCzlB44t

[IRLAB Therapeutics @IRLABThera]

IRLAB’s Phase IIb/III study in Parkinson’s disease to target Good ON https://t.co/jwYYEegcML